Protagonist Therapeutics (PTGX) announced Monday morning that it has decided to discontinue its Phase 2b study of PTG-100. The decision was made after an independent Data Monitoring Committee deemed the study futile after reviewing interim data from the trial.
from RTT - Before the Bell https://ift.tt/2GaIK95
via IFTTT
No comments:
Post a Comment